Background: The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma (PPARG) gene is suggested to associate with diabetic nephropathy. Aim: A meta-analysis was conducted to investigate the potential association of PPARG gene polymorphisms with susceptibility to diabetic nephropathy. Methods: A comprehensive search of MEDLINE (1966 to June 2011) was conducted to identify published epidemiologic studies related to polymorphisms of the PPARG gene and diabetic nephropathy. A database search yielded 5 studies involving 2758 patients. Odds ratios (ORs) along with their 95% confidence intervals (CIs) were computed to compare the distribution of alleles and genotypes between cases and controls. Results: The combined results based on all studies showed no significant difference in genotype distribution (Pro/Pro: OR. 1.42, 95% CI, 0.96-2.09); Pro/Ala: OR, 0.74, 95% CI, 0.50-1.10; Ala/Ala: OR, 0.85, 95% CI, 0.52-1.38) between cases and controls. After stratification for race, results were similar except that patients with diabetic nephropathy had a significantly higher frequency of Pro/Pro (OR, 1.82; 95% CI, 1.17-2.85) than controls among Asians. Conclusion: This meta-analysis suggests that the Pro12Ala polymorphism of the PPARG gene may be associated with diabetic nephropathy among Asians.
Get full access to this article
View all access options for this article.
References
1.
BalakumarP, AroraMK, SinghM. 2009. Emerging role of PPAR ligands in the management of diabetic nephropathy. Pharmacol Res, 60:170-173.
2.
CaramoriML, CananiLH, CostaLAet al.2003. The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes, 52:3010-3013.
CollinsAJ, KasiskeB, HerzogCet al.2007. Excerpts from the United States Renal Data System 2006 Annual Data Report. Am J Kidney Dis, 49:A6-7S1-296.
5.
DeebSS, FajasL, NemotoMet al.1998. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet, 20:284-287.
6.
ErdoganM, KaradenizM, ErogluZet al.2007. The relationship of the peroxisome proliferator-activated receptor-gamma 2 exon 2 and exon 6 gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy. Diabetes Res Clin Pract, 78:355-359.
7.
FujisawaT, IkegamiH, KawaguchiYet al.1998. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia, 41:47-53.
8.
GayathriSB, RadhaV, VimaleswaranKSet al.2010. Association of the PPARGC1A gene polymorphism with diabetic nephropathy in an Asian Indian population (CURES-41)Metab Syndr Relat Disord, 8:119-126.
9.
GoudaHN, SagooGS, HardingAHet al.2010. The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. Am J Epidemiol, 171:645-655.
HerrmannSM, RingelJ, WangJGet al.2002. Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: The Berlin Diabetes Mellitus (BeDiaM) Study. Diabetes, 51:2653-2657.
12.
HuangX, ZhaoJ, ZhaoT. 2011. Effects of peroxisome proliferator activated receptor-gamma 2 gene Pro12Ala polymorphism on fasting blood lipids: a meta-analysis. Atherosclerosis, 215:136-144.
13.
JorsalA, TarnowL, LajerMet al.2008. The PPAR gamma 2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy. Mol Genet Metab, 94:347-351.
14.
LapiceE, PinelliM, RiccardiGet al.2010. Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients: comment on the study by Liu et al. Diabetes Care, 33:e114.
15.
LiY, TangK, ZhangZet al.2011. Genetic diversity of the apolipoprotein E gene and diabetic nephropathy: a meta-analysis. Mol Biol Rep, 38:3243-3252.
16.
LinCC, WuCT, WuLS. 2011. Ectonucleotide pyrophosphatase/phosphodiesterase 1 K173Q polymorphism is associated with diabetic nephropathy in the Taiwanese population. Genet Test Mol Biomarkers, 15:239-242.
17.
LittleJ, HigginsJP, IoannidisJPet al.2009. Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE Statement. Hum Genet, 125:131-151.
18.
LiuL, ZhengT, WangFet al.2010. Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Care, 33:144-149.
19.
MoczulskiDK, RogusJJ, AntonellisAet al.1998. Major susceptibility locus for nephropathy in type 1 diabetes on chromosome 3q: results of novel discordant sib-pair analysis. Diabetes, 47:1164-1169.
20.
NgDP, TaiBC, KohDet al.2005. Angiotensin-I converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: a meta-analysis of studies reported between 1994 and 2004 and comprising 14,727 subjects. Diabetologia, 48:1008-1016.
21.
ParkCW, KimHW, KoSHet al.2006. Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha. Diabetes, 55:885-893.
22.
PeiD, HuangYJ, HsiehCHet al.2010. The genetic background difference between diabetic patients with and without nephropathy in a Taiwanese population by linkage disequilibrium mapping using 382 autosomal STR markers. Genet Test Mol Biomarkers, 14:433-438.
23.
PollexRL, MamakeesickM, ZinmanBet al.2007. Peroxisome proliferator-activated receptor gamma polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. J Diabetes Complications, 21:166-171.
24.
SaleMM, SmithSG, MychaleckyjJCet al.2007. Variants of the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in an African-American population enriched for nephropathy. Diabetes, 56:2638-2642.
25.
SeaquistER, GoetzFC, RichSet al.1989. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med, 320:1161-1165.
26.
SzetoCC, ChowKM, PoonPYet al.2008. Peroxisome proliferator-activated receptor-gamma gene polymorphism and risk of cardiovascular disease in patients with diabetic nephropathy. Am J Nephrol, 28:715-722.
27.
TangSC, LeungJC, ChanLYet al.2006. Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferator-activated receptor-gamma agonist. J Am Soc Nephrol, 17:1633-1643.
28.
TonjesA, ScholzM, LoefflerMet al.2006. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care, 29:2489-2497.
29.
WenMJ, LinCJ, HungYJet al.2011. Association study between apolipoprotein E gene polymorphism and diabetic nephropathy in a Taiwanese population. Genet Test Mol Biomarkers 10.1089/gtmb.2010.0201.
30.
WuLS, HsiehCH, PeiDet al.2009. Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes. Nephrol Dial Transplant, 24:3360-3366.
31.
XuW, LiY, WangXet al.2010. PPARgamma polymorphisms and cancer risk: a meta-analysis involving 32,138 subjects. Oncol Rep, 24:579-585.
32.
ZangHL, WangCJ, YangJC. 2010. [The protective role of PPARgamma in diabetic nephropathy]Sheng Li Ke Xue Jin Zhan, 41:435-438.
ZintzarasE, StefanidisI. 2005. Association between the GLUT1 gene polymorphism and the risk of diabetic nephropathy: a meta-analysis. J Hum Genet, 50:84-91.
35.
ZintzarasE, UhligK, KoukoulisGNet al.2007. Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy: a meta-analysis. J Hum Genet, 52:881-890.
